DNA Binding Properties of Novel Pyrrolyl Quinones Derivatives: Insights from Spectroscopic, Electrophoretic and Computational Studies Authors: Sandra G. Barbosa-Muñoz, Melissa Tapia-Juárez, Diana S. Ramírez-Guzmán, Salvador Gallardo-Alfonzo, Fabián Orozco-López, César R. Solorio-Alvarado, Carlos J. Cortés-García, Luis Chacón-García Published: 2026 ABSTRACT In this work, we report the synthesis and Deoxyribonucleic acid (DNA)-binding properties of a new series of pyrrolyl quinone derivatives. These compounds were prepared from 2,5-dimethyl-1,4-benzoquinone through Michael-type addition/oxidation and electrophilic aromatic substitution reactions using pyrrole and bis-pyrrole nucleophiles. Additional structural diversification was achieved by reacting the pyrrolyl quinone intermediate either with 1-aminoanthracene or with acetone, affording new pyrrolyl quinone derivatives through distinct synthetic pathways. Owing to the electron-deficient π-conjugated nature of the pyrrolyl quinone scaffold, their ability to interact with DNA was investigated by ultraviolet–visible (UV–vis) spectroscopy, gel electrophoresis, viscosity studies and molecular docking analyses. The combined results demonstrate that these new pyrrolyl quinone derivatives interact with DNA, highlighting the potential of this scaffold as a promising platform for molecular recognition and future drug-design applications. Introduction Small molecules interact with Deoxyribonucleic acid (DNA) through distinct noncovalent binding modes, including intercalation, groove binding, and electrostatic interactions. Intercalating agents insert between DNA base pairs, oriented perpendicular to the helical axis of DNA and stablishing noncovalent interactions such as hydrogen bonds, van der Waals forces, and hydrophobic contacts, which collectively stabilize the resulting DNA–ligand supramolecular complex., − Upon intercalation, the ligand causes a decrease in the DNA helical twist and an elongation of the double helix, leading to conformational changes in the biomolecule. ,, Although such interactions do not directly damage the genetic material, the formation of DNA–ligand complexes can inhibit key enzymes involved in DNA replication, such as DNA polymerases and topoisomerases, ,, thereby suppressing the rapid proliferation of cancer cells and contributing to their use as antitumor agents. ,, Moreover, the unique recognition properties of these systems also open possibilities for other applications, including molecular diagnostics. , An intercalating agent must exhibit specific structural and electronic properties to insert between DNA base pairs, particularly molecular planarity and electron deficiency. These features are commonly associated with systems containing fused bicyclic or tricyclic aromatic rings. However, several intercalating agents with nonfused rings, referred to as atypical intercalators, have also been reported. ,, Representative examples include acridine, daunorubicin, and prodigiosin (Figure ), which, despite their distinct chemical frameworks, share the ability to intercalate into DNA, highlighting the structural diversity among molecules with this biological activity. Structures of typical (1–2) and atypical (3) intercalators. Several compounds containing benzoquinone motifs have been reported to associate with genetic material. Doxorubicin and daunorubicin (Figure , compound 2) are examples of typical intercalators with potent antitumor activity, both containing a quinone subunit. , Additionally, prodigiosin (Figure , compound 3) is an atypical intercalator with anticancer properties featuring unfused pyrrole rings. Although a variety of DNA-binding compounds and polycyclic quinone-based intercalators have been extensively investigated, ,, the direct use of simple pyrrolyl quinones as DNA-interacting scaffolds has not been previously reported. Reported systems such as pyrroloquinoline quinone, anthraquinone–pyrrole probes, and pyrroloiminoquinone alkaloids, , involve either fused polycyclic frameworks, natural-product-like architectures, or redox-active probes designed for detection purposes. In contrast, the PQ derivatives described herein are nonfused 1,4-benzoquinone–pyrrole conjugates whose electron-deficient π-system can promote DNA binding without requiring a large classical polyaromatic intercalating core. This structural distinction provides a meaningful basis for exploring PQs as atypical DNA-interacting scaffolds. We have previously reported the synthesis of a series of pyrrolyl quinones (PQ) 4–8, which are compounds derived from 1,4-benzoquinones functionalized with pyrrole (Figure a). These compounds have demonstrated remarkable versatility, acting as optical sensors that recognize metal cations and anions, including fluoride. − Furthermore, certain pyrrolyl quinone derivatives exhibit reversible redox behavior, enabling their use as catalysts in oxidative amidation reactions of aldehydes and as molecular switches and as inhibitors of mitochondrial complex III in Saccharomyces cerevisiae. , Therefore, given this combination of electronic deficiency and structural conjugation within the PQ framework, which enables these systems to participate in diverse supramolecular recognition processes, we designed and synthesized new pyrrolyl quinone derivatives 9–12 (Figure b) to investigate their interactions with DNA. (a) Representative PQ derivatives previously reported by our research group showing applications as optical sensors, catalyst in oxidative amidation reactions of aldehydes and redox-active systems. (b) Our target molecules. Considering their electron-deficient π-systems and previously demonstrated capacity for noncovalent/anion recognition, these new derivatives were evaluated as DNA-interacting scaffolds using ultraviolet–visible spectroscopy (UV–vis), gel electrophoresis, viscosity, and molecular docking studies to gain new insights into the structural features governing their binding behavior. Results and Discussion Chemistry The study began with the synthesis of the new PQ derivatives 9–12, following the general reaction sequence depicted in Scheme . The synthetic strategy relied on the well-established reactivity of 2,5-dimethyl-1,4-benzoquinone toward Michael Addition Reaction with pyrrole-based nucleophiles. Accordingly, the preparation of compounds 9 and 10 was accomplished following a procedure previously developed by our research group, in which dipyrromethane derivatives 13 and 14 reacted with 2,5-dimethyl-1,4-benzoquinone to afford 9 and 10 in 31% and 34% yield, respectively. General Synthetic Scheme for the Preparation of PQ Derivatives 9, 10, 11, and 12 On the other hand, the synthesis of compounds 11 and 12 was carried out from the key intermediate PQ 4, obtained via a Michael-type addition/oxidation sequence between pyrrole and 2,5-dimethyl-1,4-benzoquinone under mechanochemical conditions, in 44% yield. The formation of PQ 4 can be rationalized by an initial 1,4-Michael-type addition of pyrrole to the electron-deficient 2,5-dimethyl-1,4-benzoquinone, generating a reduced cyclohexadienone species that subsequently undergoes oxidation under the reaction conditions to restore the conjugated quinone system, affording the pyrrolylquinone scaffold PQ 4. Thus, compound 11 is proposed to form through the reaction between PQ 4 and acetone via the following sequence: initially, PQ 4 undergoes a 1,2-addition to acetone to generate a tertiary alcohol species, which subsequently dehydrates under the acidic conditions to afford a benzylic-type carbocation stabilized by conjugation with the quinone π-system. This electrophilic species is then attacked by a second molecule of PQ 4, during which the pyrrolic ring undergoes electrophilic aromatic substitution (SEAr), ultimately furnishing the bis-pyrrolylquinone derivative 11 in 20% yield. Interestingly, treatment of PQ 4 with 1-aminoanthracene did not afford to the expected addition–oxidation product 16; instead, compound 12 was obtained through the mechanistic pathway proposed in Scheme . The reaction is initiated by condensation between PQ 4 and 1-aminoanthracene 15, affording the imine intermediate 17. Formation of this imine increases the electron density at the γ-position of the anthracene ring through conjugation with the quinone π-system, thereby activating this position toward electrophilic aromatic substitution (SEAr) with a second equivalent of PQ 4. This process furnishes intermediate 18, which subsequently undergoes spontaneous oxidation to restore the aromaticity of the anthracene ring and generate the iminoquinone 19. Finally, hydrolysis of 19 affords the aminoanthracene–pyrrolyl quinone derivative 12. Proposed Reaction Mechanism for the Formation of Compound 12 UV–Vis Studies for PQ Derivatives-DNA Interactions UV–Vis spectroscopy is one of the simplest and most informative techniques for probing interactions between DNA and small molecules, as changes in the electronic absorption profile often reflect the binding mode. , Typically, the absorption spectrum of the free ligand is compared with that obtained after incremental addition of DNA, and deviations between the two spectra provide evidence of DNA–ligand complex formation. To explore the binding behavior of PQ derivatives 9–12, UV–vis titrations were carried out by gradually increasing the concentration of calf thymus DNA (ctDNA) (Figure ). (a) Interaction of pirrolylquinone derivatives 9–12 with ctDNA. UV–vis absorption spectra of 45 μM of A:9, B:10, C: 11, D:12 treated with 0, 15, 30, 45, 60, 75 and 90 μM of DNA (1–7). All experiments were carried out at room temperature in 0.5× TBE buffer, pH 7.8. Compounds that intercalate between DNA base pairs typically produce hypochromism and bathochromism owing to π–π stacking interactions between the aromatic chromophore and the DNA bases. ,, The degree of hypochromism correlates with the strength of this interaction, as it arises from perturbation of the electronic transition moments when the ligand enters the hydrophobic base-pair stack. In contrast, electrostatic interactions are more commonly associated with hyperchromism, an increase in absorbance upon ligand binding. ,, As shown in Figure , all four PQ derivatives exhibit a progressive decrease in absorbance intensity with increasing DNA concentration, indicating strong interactions consistent with intercalative binding. Additionally, each compound exhibits characteristic shifts in the maximum absorption wavelength (λmax), described as follows: Compound 12 (Figure D) shows a bathochromic shift of 3.75 nm in its λmax at 253 nm. This region contains overlapping bands from both DNA and the ligand; nevertheless, the observed redshift supports an intercalative mode of binding. Compound 11 (Figure C) exhibits an absorption maximum at 564 nm, accompanied by a bathochromic shift of 15.5 nm upon DNA additionan expected behavior for classical intercalators. This effect arises from stabilization of the excited state due to π–π stacking with the DNA bases, which lowers the energy of the corresponding π–π* transition. ,, In contrast, compounds 9 and 10 (Figure A,B), which also display absorption bands around 564 nm, undergo hypsochromic shifts of 17.75 and 19.75 nm, respectively. Although less common among intercalators, such blueshifts have been reported for certain systems, including the intercalative agent methotrexate, and may reflect differences in substituent effects, chromophore environment, or binding orientation within the DNA base stack. As a control, PQ 4 was also tested under the same conditions, and no visible effect was observed in the UV–vis spectrum. Determination of the DNA Binding Constants The intrinsic DNA-binding constants (K b) were determined from absorbance changes at 260 nm using a previously reported method. Double-reciprocal plots of 1/(A – A 0) versus 1/[ligand] yielded linear correlations in all cases (r > 0.90), from which the binding constants were calculated from the slope and intercept of the linear regressions according to the corresponding Benesi-Hidebrand relationship. The intrinsic binding constants obtained for the ligand–DNA interactions were as follows: compound 9, log10(K b) = 4.22; compound 10, log10(K b) = 4.19; compound 11, log10(K b) = 4 .61; and compound 12, log10(K b) = 4.39. These values are consistent with moderate DNA-binding affinity and are compatible with an intercalative contribution to the ligand–DNA interaction. , The plots of the DNA binding constant are shown in Figure . Determination of the binding constant (K b) for compounds 9 (A), 10(B), 11 (C), and 12 (D). The plots were obtained by graphing 1/(A – A 0) versus 1/ligand concentration, where A 0 is the absorbance of free DNA (90 μM) at 260 nm and A corresponds to the absorbance of the DNA–ligand complex at increasing ligand concentrations from 6.46 to 45.2 μM. Gel Electrophoresis Studies The Gel electrophoresis is a widely used method to assess direct DNA–ligand interactions, as changes in the electrophoretic mobility of plasmid DNA often reflect alterations in DNA topology induced by the compounds under study. To obtain further evidence of the interaction between the PQ derivatives and DNA, electrophoretic assays were performed using the supercoiled plasmid pBR322 (Figures –). Gel electrophoresis assay of pBR322 plasmid DNA interactions with compound 12. A total of 10 μg of compound and 250 ng of plasmid were incubated during 2,4,8 and 24 h at 37 °C. Lane 1:10,000 bp molecular weight marker; lane 2: DNA alone; lane 3: DNA + DMSO; lane 4: DNA + 15 (positive control); lane 5: DNA + 4; lane 6: DNA + 12 /24h; lane 7: DNA + 12/8h; lane 8: DNA+ 12/4h; lane 9: DNA + 12/2h. Plasmid DNA can exist in different topological isoforms, among which the supercoiled (form II) and relaxed (form I) conformations predominate. The supercoiled isoform migrates faster through agarose gel because its compact structure facilitates passage through the matrix. In contrast, the relaxed isoform displays slower mobility due to its open circular topology, which reduces its mobility through the gel. Intermediate forms (form III), resulting from partial nicking or structural alterations, exhibit migration rates between those of the supercoiled and relaxed isoforms. , The relative band intensities also provide qualitative information on the proportions of each DNA isoform. Significantly, when a molecule intercalates between DNA base pairs, it decreases the helical twist and increases the length of the DNA duplex, , leading to a conformational change from a supercoiled to a more relaxed topology. Thus, the appearance of relaxed DNA bands or changes in the supercoiled/relaxed ratio can serve as diagnostic indicators of intercalative binding. As an initial assay, the interaction between compound 12 and pBR322 plasmid DNA was evaluated at different incubation times by agarose gel electrophoresis (Figure ). The pBR322 plasmid DNA used in this assay (Figure ) consists predominantly of the supercoiled isoform, which represents approximately 90% of the sample. In lanes 2 and 3, corresponding to DNA alone and DNA/DMSO (vehicle control), the plasmid remains mainly in the supercoiled form (II), as indicated by the higher intensity of the lower band compared with the relaxed (I) one. In lane 4, the positive control (1-aminoanthracene 15) produces a decrease in the supercoiled isoform (49.4%) accompanied by an increase in the relaxed form (39.5%) and a slight increase in the intermediate isoform (III). This response is consistent with the known intercalative properties of aminoanthracene and confirms the assay’s sensitivity. In lane 5, the PQ precursor 4 exhibits weaker interaction with DNA: although a slight increase in the relaxed form (18.2%) is observed, the supercoiled isoform remains the major one (75.0%). This suggests that PQ interacts with DNA only modestly under the tested conditions. In contrast, compound 12 (lane 6), after 24 h of incubation, shows a band distribution very similar to that of the positive control: a marked reduction in the supercoiled isoform (38.6%) and a corresponding increase in the relaxed form (48.9%). These changes indicate that compound 12 interacts strongly with DNA and likely binds through an intercalative mechanism. However, at shorter incubation times (lanes 7, 8, and 9; 8, 4, and 2 h, respectively), no significant changes in DNA topology were detected, suggesting that the interaction between compound 12 and DNA under the test conditions is time-dependent. A second electrophoretic assay was performed to evaluate the interaction of compounds 9, 10, and 11 with DNA under conditions analogous to those used for compound 12. As shown in Figure , all three derivatives (lines 5–7) induce a shift from the supercoiled (II) to the relaxed (I) isoform. This consistent topological transition suggests that compounds 9–11 also interact with plasmid DNA, most likely through an intercalative binding mode similar to that observed for compound 12. Gel electrophoresis assay of pBR322 plasmid DNA interactions with compounds 9–11. A total of 10 μg of compounds and 250 ng of plasmid were incubated for 24 h at 37 °C. Lane 1:10,000 bp molecular weight marker; lane 2: DNA alone; lane 3: DNA + DMSO; lane 4: DNA + 4; lane 5: DNA + 11; lane 6: DNA + 9, lane 7: DNA + 10. To enable a more direct comparison of the DNA-binding abilities of the four compounds, a final electrophoretic assay was performed using higher concentrations and equimolar amounts of each ligand. The corresponding results are shown in Figure . Gel electrophoresis assay of pBR322 plasmid DNA interactions with compounds 9–12. A total of 0.25 μmol of compounds and 250 ng of plasmid were incubated for 24 h at 37 °C. Lane 1:10,000 bp molecular weight marker; lane 2: DNA alone; lane 3: DNA + DMSO; lane 4: DNA + 15; lane 5: DNA + 4; lane 6: DNA + 12; lane 7: DNA + 11; lane 8: DNA + 9; lane 9: DNA + 10. In Figure , lanes 6–9 (corresponding to DNA incubated with compounds 12, 11, 9, and 10, respectively) show a decrease in the supercoiled isoform (II) together with an increase in the relaxed isoform (I). This behavior further confirms that all four compounds interact with DNA, promoting a topological transition that is consistent with an intercalative binding mode. The most pronounced effect is observed in lane 7, corresponding to compound 11, where the supercoiled isoform (II) almost completely disappears. This strong topological perturbation correlates with the highest intrinsic binding constant (K b) determined for compound 11 (Figure ), as well as with its UV–Vis behavior, which exhibited both hypochromism and a marked bathochromic shifttypical signatures of intercalation (Figure ). Compounds 10 and 9 induce a less extensive isoform conversion, in agreement with their lower binding constants and the minor spectroscopic shifts observed in their titration assays. Altogether, these results reflect a consistent trend across the different experimental techniques used. The quantitative analysis of band intensities from the gel electrophoresis experiments shown in Figures – is provided in the Supporting Information (Tables S1–S3). Considering that compounds 11 and 12 exhibited the most significant activity across the techniques described above (UV–vis spectroscopy, Kb determination, and electrophoretic assays), subsequent studies focused on these two derivatives. Accordingly, additional experiments, including viscosity measurements, were performed to further investigate their interactions with DNA and gain deeper insight into their possible binding mode. Viscosity Studies The measurement of DNA relative viscosity is a well-known method for distinguishing the type of interaction that occurs when a ligand binds to this biomolecule. Although optical spectroscopic techniques provide significant evidence for DNA interaction, they are not always sufficient to unequivocally establish the binding mode. , In the case of classical intercalation, insertion of the ligand between adjacent base pairs results in an elongation of the DNA helix, and consequently an increase in its viscosity. , In contrast, when groove binding occurs, the viscosity remains unchanged or slightly decreased. ,, To obtain additional evidence regarding the interaction between DNA and PQ derivatives 11 and 12, relative viscosity measurements were performed. Experiments were carried out using a DNA solution at constant concentration, to which increasing concentrations of the compounds were added. The relative viscosity was then determined according to η = (t – t 0)/t 0, where t and t 0 correspond to the flow times (in seconds) of the DNA-ligand samples and buffer, respectively. The values of (η/η0)1/3, where η0 corresponds to the viscosity of free ctDNA, were plotted against the [ligand]/[DNA] ratio; the results are shown in Figure . , Relative viscosity of a 303 μM ctDNA solution in the presence of increasing concentrations (0–150.7 μM) of PQ derivatives. Derivative 12 (red line) and derivative 11 (black line). Experiments were performed at 37 °C in 0.5 X TBE buffer. Figure displays an increase in the relative viscosity of ctDNA upon the addition of increasing concentrations of compound 11 (black line). This behavior is consistent with a classical intercalative binding mode, in which insertion of the ligand between adjacent base pairs elongates the DNA helix and consequently increases solution viscosity. In contrast, compound 12 (red line) produces a less pronounced effect on DNA viscosity, suggesting a less efficient intercalative contribution. Control experiments performed using buffer solutions containing increasing concentrations of the compounds in the absence of ctDNA showed no appreciable changes in flow time, indicating that the observed viscosity changes are associated with DNA–ligand interactions rather than with intrinsic effects of the compounds on the solvent system. Docking Studies Molecular docking studies were performed to provide additional insight into the possible DNA-binding modes, binding affinity, and key intermolecular interactions responsible for stabilization of the ligand–DNA complexes. , For this purpose, docking simulations of compounds 9–12 with DNA were performed using the three-dimensional structure of the DNA hexamer (PDB ID: 1Z3F). , The calculated binding free energies (ΔG_bind) are summarized in Table . 1Calculated Binding Free Energies (ΔG_bind) for Compounds 9–12 Docked into DNAcompoundAutodock ΔG bind, kcal/mol 9 –8.09 10 –7.51 11 –9.09 12 –10.14 Calculated Binding Free Energies (ΔG_bind) for Compounds 9–12 Docked into DNA Compounds 11 and 12 exhibit the most favorable binding energies, consistent with their higher intrinsic binding constants (K b) (Figure ). These computational results are consistent with the UV–vis titration data, in which compounds 11 and 12 exhibited the most pronounced hypochromic and bathochromic shifts (Figure ), as well as with the electrophoresis assays where both compounds induced the most significant supercoiled-to-relaxed DNA isoform transition (Figure ). These findings are further supported by viscosity measurements, in which compound 11 promoted DNA unwinding, accompanied by an increase in solution viscosity (Figure ). As illustrated in Figure , all four compounds occupy the same intercalation site as the reference ligand ellipticine (RMSD = 0.840 Å), inserting between base pairs C1–G2 of chain A and C5–G6 of chain B of the DNA hexamer. In all cases, intercalation is stabilized by extensive π–π stacking and π–π alkyl interactions with the flanking base pairs. Compound 12 (Figure D) establishes two hydrogen bonds within the binding region: one between the pyrrole NH and the carbonyl oxygen of G2 (chain A), and another between a quinone oxygen and the amino hydrogen of the same base pair. In compound 12, the aminoanthracene fragmentknown to be a classical intercalatoris the moiety inserted between the base pairs, whereas the PQ portion remains oriented toward the solvent-exposed region of the groove. This spatial arrangement could enable additional interactions with other biomolecules in a cellular context. Predicted binding modes and interaction diagrams of compounds 9 (A), 10 (B), 11 (C), and 12 (D) (shown in gray) within the intercalation site of the DNA duplex PDB ID: 1Z3F. For compounds 9, 10, and 11, the PQ core itself serves as the intercalating chromophore. Compound 11 (Figure C) forms two hydrogen bonds: one between the pyrrole NH and the carbonyl oxygen of G2 (chain A), and another between a quinone oxygen and the amino hydrogen of A3 (chain B). Compounds 9 (Figure A) and 10 (Figure B) show similar π-stacking patterns but form fewer or weaker hydrogen-bonding interactions, consistent with their lower binding energies and weaker experimental responses. Unlike many classical DNA intercalators, which typically rely on highly extended polyaromatic systems, compounds 9–11 appear to interact with DNA through the pyrrolyl quinone scaffold itself. This observation suggests that pyrrolyl quinones may represent atypical DNA-binding scaffolds with intercalative features, thereby expanding the structural diversity of small molecules capable of interacting with DNA. Finally, based on the experimental and in silico results of the interaction of pyrrolyl quinones with DNA, we considered it worthwhile to conduct some biological activity assays to pave the way for future research. For this purpose, we selected compound 12 to evaluate its antiproliferative activity in MCF-7 cells. The results summarized in Figure show that at 6.25 μM, compound 12 exhibits over 50% inhibition of cell proliferation. These results are encouraging and warrant further investigation. Inhibition of cell proliferation in MCF-7 cells after treatment with increasing doses of compound 12 to 6.25, 12.5, 25, 50, 100, and 200 μM respectively. The control is untreated cells. Conclusions The four new pyrrolyl quinone derivatives (9–12) synthesized and evaluated, by UV–Vis titrations and agarose gel electrophoresis, demonstrated their ability to form supramolecular interactions with DNA, consistent with intercalative binding. Molecular docking analyses supported this behavior by revealing favorable insertion between DNA base pairs and identifying stabilizing noncovalent interactions Overall, these results underscore the potential of the pyrrolyl quinone scaffold as a versatile platform for developing new DNA-binding molecules, with possible applications in molecular recognition, sensing, diagnostic technologies and particularly in the search for new alternative compounds with antiproliferative activity in cell lines. Experimental Section General Information All Reagents were purchased from Sigma-Aldrich and used without further purification, and only Pyrrole was distilled immediately prior to use. Solvents were obtained commercially in analytical and HPLC grades. The products were purified by flash column chromatography (silica gel Sigma-Aldrich, 230–400 mesh). Chemical names and drawings were obtained using ChemDraw Professional (version 15.0.0.106). Melting points were determined on a Fisher-Johns melting point apparatus and are uncorrected. NMR spectra were recorded in a Varian Mercury spectrometer (400 MHz), Bruker Advance III spectrometer (500 MHz) and Jeol JMN-ECZ (400 MHz). NMR spectra were analyzed using the MestreNova software (version 6.0.2–5475) UV–vis spectra were obtained on a spectrophotometer Genesys 10S UV–vis Thermo Scientific, and the graphics were obtained using OriginPro (version 9.0.0). General Procedure for 2,5-Dimethyl-3-(1H-pyrrol-2-yl)­cyclo­hexa-2,5-diene-1,4-dione (4) The synthesis of compound 4 was carried out following the protocol previously reported by our research group. In a porcelain mortar, 2,5-dimethyl-1,4-benzoquinone (0.10 g, 0.73 mmol, 1.0 equiv), SiO2 (23% w/w), and pyrrole (0.20 mL, 2.8 mmol, 3.8 equiv) were added and ground with a porcelain pestle at room temperature. After 5 min of grinding, 5 drops of CH2Cl2 [1.3 M] were added, producing an immediate color change to deep purple. Grinding was continued for an additional 10 min, followed by the addition of 5 more drops of CH2Cl2 and the mixture was further ground for another 10 min. The reaction progress was monitored by TLC until complete consumption of the starting benzoquinone was observed. The crude residue was purified by column chromatography (hexane/EtOAc 98:2 v/v) to afford compound 4 as a red solid (65 mg, 44%). R f = 0.6 (Hex: EtOAc 8:2 v/v), m.p 98–100 °C. The 1H and 13C NMR spectra were consistent with the data reported by us.1 1H NMR (400 MHz, CDCl3): δ = 10.70 (bs, 1H), 7.04 (m, 1H), 6.70–6.68 (m, 1H), 6.60 (d, J = 1.6 Hz, 1H), 6.36–6.35 (m, 1H), 2.28 (m, 3H), 2.05 (d, J = 1.6 Hz, 3H). 13C NMR (100 MHz, CDCl3): δ = 190.8, 187.0, 144.7, 134.9, 133.5, 131.7, 125.3, 122.3, 117.2, 109.9, 15.9, 14.7. HRMS (ESI+): m/z, Calcd for C12 H11 N O2 [M + H] + : 201.0790; found 201.0783. General Procedure for 3-(5-(1-(1H-Pyrrol-2-yl)­cyclo­hexyl)-1H-pyrrol-2-yl)-2,5-di­meth­yl­cyclo­hexa-2,5-diene-1,4-dione (9) The synthesis of compound 9 was carried out according to a previously reported procedure by our research group, with slight modifications. A solution of meso-cyclohexyldipyrromethane (0.157 g, 0.732 mmol, 1.0 equiv) in CH2Cl2 [0.4 M] was prepared, and 2,5-dimethyl-1,4-benzoquinone (100 mg, 0.734 mmol, 1.0 equiv) was added at room temperature. SiO2 (7% w/w) was then incorporated, and the solvent was subsequently removed by evaporation at room temperature. The resulting solid-phase mixture was left to react for 24 h without stirring. The crude residue was purified by column chromatography (hexane/EtOAc 9:1 v/v) to afford compound 9 as a purple solid (81 mg, 31%). R f = 0.4 (Hex: EtOAc 8:2 v/v), mp 129–130 °C. 1H NMR (400 MHz, CDCl3) δ 10.40 (bs, 1H), 7.87 (s, 1H), 6.68–6.65 (m, 2H), 6.56 (d, J = 1.6 Hz, 1H), 6.22–6.19 (m, 2H), 6.16–6.14 (m, 1H), 2.24 (s, 3H), 2.17 (t, J = 5.9 Hz, 3H), 2.01 (d, J = 1.6 Hz, 3H), 1.67–1.54 (m, 5H), 1.52–1.48 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 191.0, 187.0, 144.6, 143.5, 136.9, 133.7, 133.7, 133.6, 131.6, 124.6, 118.3, 116.8, 116.7, 108.4, 106.9, 104.7, 40.2, 36.9, 25.9, 22.8, 15.9, 14.7. HRMS (ESI+): m/z, Calcd for C22 H24 N2 O2 [M + H] + : 348.1838; found 348.1825. General Procedure for 3-(5-(3-(1H-Pyrrol-2-yl)­pentan-3-yl)-1H-pyrrol-2-yl)-2,5-di­meth­yl­cyclo­hexa-2,5-diene-1,4-dione (10) The synthesis of compound 10 was carried out according to a previously reported procedure from our research group, with slight modifications. A solution of meso-diethyldipyrromethane (147 mg, 0.726 mmol, 1.0 equiv) in CH2Cl2 [0.4 M] was prepared and 2,5-dimethyl-1,4-benzoquinone (100 mg, 0.734 mmol, 1.0 equiv) was added at room temperature. SiO2 (7% w/w) was then incorporated, and the resulting suspension was maintained for 24 h without stirring. After completion of the reaction, the solvent was removed by evaporation at room temperature. The crude residue was purified by column chromatography (hexane/EtOAc 9:1 v/v) to afford compound 10 as a purple solid (85 mg, 34%), R f = 0.5 (Hex: EtOAc 8:2 v/v), mp 105–108 °C. 1H NMR (400 MHz, CDCl3) δ 10.31 (bs, 1H), 7.87 (s, 1H), 6.70 (q, J = 2.3 Hz, 1H), 6.65–6.63 (m, 1H), 6.57 (q, J = 1.6 Hz, 1H), 6.22–6.21 (m, 1H), 6.20–6.16 (m, 2H), 2.25 (m, 3H), 2.07–2.03 (m, 4H), 2.01 (d, J = 1.5 Hz, 3H), 0.77 (t, J = 7.3 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 190.9, 187.0, 144.6, 142.4, 135.6, 133.8, 133.7, 131.7, 124.7, 117.8, 117.0, 108.3, 107.9, 106.2, 43.9, 29.8, 15.9, 14.7, 8.4. HRMS (ESI+): m/z, Calcd for C21 H24 N2 O2 [M + H] + : 336.1838; found 336.1823. General Procedure for 3,3′-(Propane-2,2-diylbis­(1H-pyrrole-5,2-diyl))­bis­(2,5-di­meth­yl­cyclo­hexa-2,5-diene-1,4-dione) (11) 2,5-Dimethyl-3-(1H-pyrrol-2-yl)­cyclohexa-2,5-diene-1,4-dione (30 mg, 0.149 mmol, 1.0 equiv) was dissolved in acetone [0.14 M], after which a methanesulfonic acid/acetone solution (0.006:0.994 v/v, 0.09 M; 100 μL, 0.0091 mmol, 0.06 equiv) was added. The mixture was stirred at room temperature for 24 h and subsequently neutralized with an aqueous NaHCO3 solution (5%). The organic phase was extracted with CH2Cl2, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by column chromatography (hexane/EtOAc 9:1 v/v) to afford compound 11 as a purple solid (10 mg, 20%), R f = 0.3 (Hex/EtOAc 8:2 v/v), m.p 118–121 °C. 1H NMR (500 MHz, CDCl3) δ 10.47 (bs, 1H), 7.19 (s, 1H), 6.61 (dd, J = 3.9, 2.6 Hz, 2H), 6.51 (q, J = 1.6 Hz, 2H), 6.19 (dd, J = 3.9, 2.8 Hz, 2H), 2.21 (s, 6H), 1.95 (d, J = 1.5 Hz, 6H), 1.72 (s, 6H). 13C NMR (125 MHz, CDCl3) δ 190.1, 186.0, 143.5, 142.4, 133.1, 132.7, 130.5, 123.9, 117.2, 105.6, 34.9, 27.6, 14.9, 13.8. HRMS (ESI+): m/z, Calcd for C27 H26 N2 O4 [M + H]+: 442.1893; found 442.1907 General Procedure 3-(5-(4-Aminoanthracen-1-yl)-1H-pyrrol-2-yl)-2,5-di­meth­yl­cyclo­hexa-2,5-diene-1,4-dione (12) 2,5-Dimethyl-3-(1H-pyrrol-2-yl)­cyclohexa-2,5-diene-1,4-dione (50 mg, 0.248 mmol, 1.0 equiv) was dissolved in CH2Cl2 [0.25 M], followed by the addition of 1-aminoanthracene (46 mg, 0.238 mmol, 1.0 equiv). Silica gel (4.7% w/w) was then added, and the solvent was removed under ambient conditions. The resulting solid mixture was stirred for 24 h at room temperature. After completion, the crude material was purified by column chromatography (Hexane/EtOAc 7:3 v/v) to afford compound 12 as a green solid (13.4 mg, 14%). 1H NMR (400 MHz, DMSO-d 6) δ 11.15 (s, 1H), 8.86 (d, J = 16.3 Hz, 2H), 8.04–8.01 (m, 2H), 7.49 (d, J = 9.7 Hz, 2H), 7.49 (d, J = 9.7 Hz, 2H), 7.49 (d, J = 9.7 Hz, 2H), 6.73 (d, J = 7.6 Hz, 1H), 6.73 (d, J = 7.6 Hz, 1H), 6.56–6.55 (m, 1H), 6.17 (s, 2H), 2.25 (s, 3H), 2.05 (d, J = 1.5 Hz, 2H). 13C NMR (100 MHz, DMSO- d 6) δ 187.8, 187.0, 144.9, 144.7, 135.5, 134.5, 134.2, 133.2, 131.3, 130.1, 129.8, 128.2, 128.1, 127.9, 125.8, 125.2, 123.7, 123.6, 122.9, 121.5, 117.7, 116.7, 109.6, 104.5, 15.6, 13.8. HRMS (ESI+): m/z, Calcd for C26 H21 N2 O2 [M + H]+: 393.16030; found 393.15974. UV–Vis Measurements To perform the titrations, solutions of compounds 9–12 (45 μM) were kept at a constant concentration in 0.5× TBE buffer, while increasing amounts of ctDNA solution were added in the range of 0 to 90 μM (0–60 μg/mL). The DNA used in these experiments was ctDNA (Invitrogen). , UV absorption spectra were recorded on Genesys 10s UV–visible spectrophotometer at 298 K in the wavelength range of 225–700 nm. The quartz cuvette with 1 cm path length was used. Determination of the DNA Binding Constants To determine the binding constant (K b) of the compounds, titrations were performed by keeping constant the concentration of ctDNA (90 μM) in 0.5× TBE buffer, while increasing amounts of each compound were added in the range of 6.46 to 45.2 μM. A Genesys 10s UV–vis spectrophotometer, Thermo Scientific, was employed to obtain the absorbances at 260 nm (A 0 corresponds to the absorbance of free DNA, while A corresponds to the absorbance measured after each incremental addition of ligand). Binding constants were calculated from the slope and intercept of the linear regressions according to the corresponding Benesi-Hidebrand relationship. Gel Electrophoresis Studies pBR322 plasmid DNA solution (Invitrogen) was employed, as well as solutions of the compounds at the concentrations described in each test. The agarose (Invitrogen) gels were prepared at 1% in 0.5× TBE buffer. The electrophoretic run was carried out at 90 V, in an OWL brand electrophoresis chamber with 300 mL of 0.5× TBE buffer (Tris-borate-EDTA), using a THERMO brand power source. To reveal the gel, a 0.025% ethidium bromide solution was employed, using a THERMO brand UV transilluminator for visualization. Incubation was carried out at 37 °C and at 300 rpm in an EPENDORF thermomixer for the time intervals described in each assay. An analysis of the band intensities of the electrophoresis assays (Figures , , and ) was carried out using version 6.1 of the image-lab-software BIO-RAD, the results are shown in the supporting section. Viscosity Studies Viscosity measurements were performed using a Micro-Ostwald viscometer with 3 mL of a ctDNA solution (303 μM, corresponding to 200 μg/mL) prepared in 0.5× TBE buffer. Increasing concentrations of each compound were added incrementally to reach final concentrations ranging from 0 to 150.7 μM, while the temperature was maintained at 37 °C. The relative viscosity was then determined according to η = (t – t 0)/t 0, where t and t 0 correspond to the flow times (in seconds) of the DNA-ligand samples and buffer, respectively. The values of (η/η0)1/3, where η0 corresponds to the viscosity of free ctDNA, were plotted against the [ligand]/[DNA] ratio. , Cell Proliferation Treated MCF-7 cells were incubated in methanol and washed twice with distilled water. A solution of 0.1% crystal violet was used to dye cells; the crystal violet recovered with 10% acetic acid was used for analysis in microplate reader Multiskan GO Spectrophotometer (Thermo Scientific, Ratastic, Finland). Cell proliferation was quantified after treatment with increasing doses of compound 12 to 6.25, 12.5, 25, 50, 100, and 200 μM respectively. Molecular Docking Studies The chemical structures of compounds 9–12 were modeled as 2D structures using the ChemBio Ultra 13.0 software and subsequently converted into 3D models using the Avogadro program. In Avogadro, the protonation state of each compound was adjusted to reflect physiological pH (7.4), and the resulting geometries were optimized using the UFF force field. The DNA crystal structure was retrieved from the Protein Data Bank (PDB ID: 1Z3F). , Initially, water molecules were removed from the macromolecular structure using PyMOL. subsequently, the geometry of the system was minimized with the YASARA2 force field implemented in the YASARA minimization server. After the cocrystallized ligand was removed, the minimized structure (saved in *.pdb format) was used for molecular docking of each ligand. The results from docking simulations were visualized using Chimera whereas 2D-interaction diagrams were produced with Discovery Studio visualizer 2021. The protocol for docking simulations was as follows: blind molecular docking was performed through Autodock 4.2. The graphical interface AutodockTools 1.5.6 suite was used to prepare and analyze docking simulations, nonpolar hydrogen atoms were removed and Kollman charges were assigned to the atoms of DNA. For the ligand, rotatable bonds, degrees of freedom, Gasteiger partial charges and polar hydrogen atoms were defined. Both DNA and ligand structures were exported as *pdbqt files. Docking simulations using Autodock 4.2 were performed employing the AutoDock semiempirical free-energy scoring function with a grid box size of 72 Å × 72 Å × 72 Å with a spacing of 0.345 Å, and coordinates x = 2.368, y = 15.796, and z = 37.552. To validate the docking protocol, the structure of cocrystallized ligand ellipticine was redocked under the same conditions. After superposing the binding pose of the redocked structure onto the native pose of ellipticine, a root-mean-square deviation (RMSD) value of 0.840Å was obtained, depicting the accuracy of the program. The superposition between the crystallographic and redocked conformations of ellipticine is shown in Figure . Validation of the docking protocol by redocking of the cocrystallized ligand ellipticine into the DNA structure (PDB ID: 1Z3F). Superposition of the crystallographic pose (gray) and the redocked pose (yellow) yielded an RMSD value of 0.840 Å. The search was carried out with the Lamarckian Genetic Algorithm. A total of 100 GA runs were performed, with a maximum of 250 000 evaluations, a mutation rate of 0.02, and an initial population of 150 conformers. Finally, the lowest-energy conformation from the most populated cluster was selected for each ligand to be used in further analysis. Supplementary Material